Adrenal Update

Pheochromocytoma Management

Friday, April 26
1:55 PM - 2:25 PM
Location: Convention Center 152

Learning Objectives:

Camilo Jimenez, MD

Professor
The University of Texas MD Anderson Cancer Center

Camilo Jimenez is a Professor of Oncological Endocrinology at the University of Texas MD Anderson Cancer Center. Dr. Jimenez is the head of the Pheochromocytoma and Paraganglioma research group. This group tries to identify effective therapies for patients with pheochromocytomas and paragangliomas. Dr. Jimenez is the principal investigator of several phase 2 clinical trials for patients with metastatic pheochromocytomas and paragangliomas. One of these clinical trials led to the approval of the high specific activity MIBG for the treatment of patients with unresectable/malignant pheochromocytomas and paragangliomas by the United States Food and Drug Administration in 2018. Dr. Jimenez was the Chair of the International Society for Pheochromocytoma and Paraganglioma Research (PRESSOR) from 2011 through 2014. Dr. Jimenez has published more than 100 peer reviewed manuscripts in the field of Oncological Endocrinology.

Presentation(s):

Send Email for Camilo Jimenez


Assets

Pheochromocytoma Management

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Pheochromocytoma Management